# Suraksha Diagnostic share price today (Suraksha Diagnostic Ltd, NSE: SURAKSHA)

> Suraksha Diagnostic share price today: ₹323.70 at the NSE close on 3 November 2026, up 1.8% in a year. Suraksha Diagnostic (NSE: SURAKSHA) is worth ₹1,688 crore, trades at a P/E of 47.1 and has closed between ₹235.55 and ₹350.15 over the past 52 weeks. > Suraksha Diagnostic Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. SURAKSHA · Diagnostics · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/suraksha-diagnostic-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from fewer quarters than usual
- Price: ₹323.70 (+1.8% in a year)
- P/E: 47.1× (higher than 56% of the last 1 year)
- Revenue (Jun 2026): ₹88.0 Cr (+20.5% on a year ago)
- Profit (Jun 2026): ₹13.0 Cr (+44.4% on a year ago)
- Operating margin: 35.0% (+2.0 points on a year ago)
- ROCE: 17%, FY26
- ROIC: 12.4%, against a 12.0% cost of capital: +0.4 points

Biggest thing to watch: the price has already been rising for 8 weeks, so timing is the risk more than the business. ## What is the Suraksha Diagnostic share price today? Suraksha Diagnostic Ltd's share price was ₹323.70 at the close on 3 November 2026. It has been rising for 8 weeks. That is 8.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹236 and ₹350, and at that close it sat 77% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 14 weeks in a row. Over the last 1 year the share price moved −22% while the NIFTY 500 moved −6%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Suraksha Diagnostic this quarter? Three changes stood out: revenue up on a year earlier for 8 quarters in a row (every quarter we can compare), highest quarterly profit in 12 quarters and highest quarterly revenue in 12 quarters. 1. Revenue up on a year earlier for 8 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹88 crore, +20.5% on a year earlier. Why: Revenue rose because the company opened more centers and sold more genomics tests. Next results: check whether genomics keeps growing at the pace management indicated. From the earnings call on 13 Aug 2026. 2. Highest quarterly profit in 12 quarters Profit of ₹13 crore in the June 2026 quarter is the highest of the last 12 quarters. Why: Profit rose because mature centers did better as they handled more tests and genomics work. Next results: check whether the stated margin floor holds. From the earnings call on 13 Aug 2026. 3. Highest quarterly revenue in 12 quarters Revenue of ₹88 crore in the June 2026 quarter is the highest of the last 12 quarters. ## What are Suraksha Diagnostic's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Suraksha Diagnostic reported revenue of ₹88.0 crore, up 20.5% from ₹73.0 crore a year earlier, and a profit of ₹13.0 crore, up 44.4% from ₹9.00 crore. ### Suraksha Diagnostic results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹88.0 crore | ₹73.0 crore | +20.5% |
| Profit | ₹13.0 crore | ₹9.00 crore | +44.4% |
| Earnings per share | ₹2.50 | ₹1.80 | +38.9% |
| Operating margin | 35.0% | 33.0% | +2.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Suraksha Diagnostic's management discussed these results on a call held on 13 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Suraksha Diagnostic share price history? Suraksha Diagnostic closed at ₹323.70 on 3 November 2026, up 1.8% from ₹317.95 a year earlier (31 October 2025). Its highest weekly close since December 2024 was ₹417.25 on 6 December 2024. ### Suraksha Diagnostic share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹299.35 | +8.1% |
| 1 month ago · 1 Oct 2026 | ₹350.15 | −7.6% |
| 6 months ago · 30 Apr 2026 | ₹283.95 | +14.0% |
| 1 year ago · 31 Oct 2025 | ₹317.95 | +1.8% |
| Earliest and highest weekly close in our records · 6 Dec 2024 | ₹417.25 | −22.4% |
| Lowest weekly close since December 2024, also the 52-week low · 27 Mar 2026 | ₹235.55 | +37.4% |
| 52-week high (weekly close) · 1 Oct 2026 | ₹350.15 | −7.6% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (107 weekly closes from 6 December 2024 to 3 November 2026.)

## What is the latest news on Suraksha Diagnostic? 3 Nov 2026: Suraksha Diagnostic closed at ₹323.70, up 8.1% on the week and down 7.6% on the month. 15 Sep 2026: ex-date for a dividend of ₹0.50 a share. ### Earlier

- 13 Aug 2026: Suraksha Diagnostic held its results call for April to June 2026. Management guided: Genomics growth indicated around 20-odd% quarter-on-quarter for FY27; exact scope was not clarified. - Results for April to June 2026: Revenue up 20.5% and profit up 44.4% on a year earlier. ## What dividend does Suraksha Diagnostic pay? Suraksha Diagnostic paid ₹0.50 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.15% at the ₹323.70 close on 3 November 2026. The last was a dividend of ₹0.50 a share, ex-date 15 September 2026. ### Suraksha Diagnostic dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 15 Sep 2026 | ₹0.50 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 0 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Suraksha Diagnostic Ltd paid out 1% of its profit as dividends in FY26, and it paid a dividend in 1 of its last 7 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Suraksha Diagnostic management say on the latest results call? On the call for April to June 2026, held on 13 August 2026, Suraksha Diagnostic's management guided: Genomics growth indicated around 20-odd% quarter-on-quarter for FY27; exact scope was not clarified. > “While this remains a small base today, we believe it has the potential to become a meaningful pillar of the business as we scale the platform.”
> Dr. Somnath Chatterjee, on the call for April to June 2026

### What management guided

- FY27 operating margin not below 34%; Q2 expected strong, Q3 seasonally muted and Q4 strong. - FY28-29 operating margin expected above the 33-34% level discussed. - FY27 capital spending around ₹70-80 crore; typical setup costs are ₹10-10.5 crore per hub and ₹1.5-2 crore per spoke. - FY28 network goal 100 centers; remaining FY27 rollout stated as 3 hubs + 6 spokes in Q&A versus 4 hubs + 7 spokes in prepared materials. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/58224/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 13 August 2026.)

## What to watch in Suraksha Diagnostic's next results? When Suraksha Diagnostic reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Next-quarter operating margin to remain above the stated floor; check whether seasonal softness and further center openings dilute profitability. - What to check (from the call)
- Next-quarter operating margin to remain above the stated floor; check whether seasonal softness and further center openings dilute profitability. - Existing newer centers to continue improving; the next print should show no reversal in cohort profitability. - Genexus validation and genomic B2B adoption to convert clinical capability into sustained sequential growth. - Prepared and spoken rollout counts to reconcile in the next operating update, including the near-term Tripura launch. ## Which stock lists is Suraksha Diagnostic on? Suraksha Diagnostic is on one of our India lists: Momentum stocks. [Momentum stocks Market cap cr: 1695.4057215109847](https://www.sectoralpha.in/momentum-stocks-india)

## Is Suraksha Diagnostic profitable? Suraksha Diagnostic Ltd earned ₹13.0 Cr of net profit in the Jun 2026 quarter, +44.4% on the same quarter a year earlier. Full-year FY26 profit was ₹31.0 Cr. Over 6 years profit has grown 12.9% a year on average. That is 14.8% of the quarter's revenue. The same quarter a year earlier earned ₹9.0 Cr. For the full year, FY26 profit was ₹31.0 Cr (+0.0% on the year before). Why profit moved: revenue changed +20.5% on a year earlier and the margin moved +2.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +9.2% and revenue +23.3%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Suraksha Diagnostic make, and is it growing? Suraksha Diagnostic Ltd reported ₹88.0 Cr of revenue in the Jun 2026 quarter, +20.5% on the same quarter a year earlier. That is the 9th quarter in a row with growth on the year before. Over 6 years it has grown 11.9% a year on average. The last full year, FY26, came in at ₹310 Cr. The last four reported quarters add to ₹326 Cr. FY26 revenue was ₹310 Cr, +23.0% on the year before. Recent pace: the last four quarters grew +23.3% on average, against 11.9% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +23.0%, against +19.6% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +9.4%, against +13.9% a year (rolling over). ## How much of every ₹100 of sales does Suraksha Diagnostic keep? Suraksha Diagnostic Ltd's operating margin was 35.0% in the Jun 2026 quarter, 2.0 percentage points higher than the same quarter a year ago. Across 7 years it has been between 18.0% and 33.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +2.0 percentage points on the year while gross margin changed +0.6 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Suraksha Diagnostic's profit turning into cash? Over the last 3 years, 241% of Suraksha Diagnostic Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹82.0 Cr of operating cash against ₹31.0 Cr of profit. After ₹159 Cr of spending on assets, free cash was −₹77.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 241% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle. What to look at next: the bigger use of cash is spending on new assets, at 2.4× depreciation over three years. The next section checks what that spending is building. ## Where does Suraksha Diagnostic's cash go? Suraksha Diagnostic Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −101 days in FY26, down from −99 days in FY21. It spent ₹264 Cr on assets over the last 3 years. Customers take 27 days to pay, and stock sits for 81 days on average. At FY26 sales of ₹310 Cr, each day of that cycle ties up about ₹0.8 Cr, so roughly −₹86.0 Cr is tied up in the business at any time. FY26: customers took 27 days to pay and stock sat for 81 days, about 2.7 months of sales sitting as stock, for a full cycle of −101 days, shorter than FY21's −99. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 81 days. Customers pay about 27 days after that. Suppliers are paid at 209 days. Together that makes the −101-day cycle. Spending on assets: ₹264 Cr over the last 3 years, against ₹109 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹37.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Suraksha Diagnostic's P/E ratio, and how does it compare with its own history? Suraksha Diagnostic Ltd's P/E is 47.1×, in the middle of its own history: higher than 56% of past readings. Its usual P/E (the middle reading) is 46.7×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +1.1% while the price moved +1.8%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Suraksha Diagnostic business getting better or worse? Suraksha Diagnostic Ltd's business is turning around. Profit growth has swung from −10.0% at its low to +44.4%, improving for 2 quarters in a row (from single-quarter figures), with ROCE steady at 18.6%. This is based on 10 quarters of 3 measures, with some gaps. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Suraksha Diagnostic earn on its capital? Suraksha Diagnostic Ltd earned a ROCE of 17% in FY26. That is up from a low of 8% in FY21. Its return on capital used (ROIC) is 0.4 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 10.0% net margin and 0.69× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 10.0% net margin × 0.69× asset turnover × 1.84× leverage (assets divided by equity) ≈ 12.7% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 12.4% − 12.0% = +0.4 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. ## Does Suraksha Diagnostic have too much debt? Suraksha Diagnostic Ltd has total debt of ₹130 Cr against shareholder equity of ₹243 Cr as of Jun 2026, so its debt is 0.53× its equity. Year by year, that ratio went from 0.50 in FY24 to 0.53 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Suraksha Diagnostic shareholding pattern? Foreign institutions cut their stake in Suraksha Diagnostic Ltd by 1.4 percentage points over 7 quarters, the biggest change among its owners. Foreign institutions now own 14.0% of the company. Domestic institutions moved +1.1 points over the same period, to 21.6%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −1.4 points over 7 quarters, to 14.0%; Domestic institutions: +1.1 points over 7 quarters, to 21.6%; Promoters: +0.3 points over 7 quarters, to 49.1%. Why the owners changed: foreign institutions drove it (−1.4 points), with the other side taken by domestic institutions (+1.1 points). They reduced their stake. ## How far is Suraksha Diagnostic from balance-sheet trouble? For Suraksha Diagnostic Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Suraksha Diagnostic rank in its industry? 57.1 out of 100, rank 5 of 9 in Diagnostics, with 89% of the evidence available. Suraksha Diagnostic Ltd scores 57.1 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 5. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 19.3 + 11.7 + 8.9 + 17.2 = 57.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Suraksha Diagnostic compared with? Suraksha Diagnostic ranks 5 of 9 Diagnostics companies on the 4-Factor Sector Score, with 57.1 out of 100. 1. [One Global Service Provider Ltd](https://www.sectoralpha.in/stocks/one-global-service-provider-ltd) ONEGLOBAL · quiet · Most evidence points up · 81% evidence 70.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 100% · Profit 100% · Operating margin change 4 points · 88% evidence Capital efficiency 14.1/25 · ROCE 87% · Operating margin 19% · 100% evidence Valuation 18.5/20 · P/E 11.6× · PEG 0.45 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -18.5% · 1 year 24.8% · 25% evidence · 0 of 5 weeks ahead Exact sum: 30.1 + 14.1 + 18.5 + 7.5 = 70.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Metropolis Healthcare Ltd](https://www.sectoralpha.in/stocks/metropolis-healthcare-ltd) METROPOLIS · turning · Evidence leans up · 96% evidence 64.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.7/35 · Revenue 21.8% · Profit 33.5% · Operating margin change 2 points · 88% evidence Capital efficiency 14.1/25 · ROCE 17.8% · Operating margin 25% · 100% evidence Valuation 13.3/20 · P/E 54.4× · PEG 1.08 · 100% evidence Relative strength 11.5/20 · Lead over its industry 3.2% · Lead over NIFTY 500 11.6% · 1 year 10.8% · 100% evidence · 4 of 12 weeks ahead Exact sum: 25.7 + 14.1 + 13.3 + 11.5 = 64.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Thyrocare Technologies Ltd](https://www.sectoralpha.in/stocks/thyrocare-technologies-ltd) THYROCARE · quiet · Evidence leans up · 100% evidence 60.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 22% · Profit 12.6% · Operating margin change 0 points · 100% evidence Capital efficiency 21.3/25 · ROCE 35.4% · Operating margin 33% · 100% evidence Valuation 12.6/20 · P/E 41.5× · PEG 1.1 · 100% evidence Relative strength 4.1/20 · Lead over its industry -6.7% · Lead over NIFTY 500 0.5% · 1 year -2% · 100% evidence · 7 of 12 weeks ahead Exact sum: 22 + 21.3 + 12.6 + 4.1 = 60 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Vijaya Diagnostic Centre Ltd](https://www.sectoralpha.in/stocks/vijaya-diagnostic-centre-ltd) VIJAYA · leader · Evidence leans up · 96% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 20.2% · Profit 23.8% · Operating margin change 4 points · 88% evidence Capital efficiency 16.4/25 · ROCE 20.5% · Operating margin 43% · 100% evidence Valuation 0.3/20 · P/E 79.4× · PEG 4.13 · 100% evidence Relative strength 18.7/20 · Lead over its industry 18.1% · Lead over NIFTY 500 26.8% · 1 year 46.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.1 + 16.4 + 0.3 + 18.7 = 59.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 5. Suraksha Diagnostic Ltd this page SURAKSHA · breaking out · Evidence leans up · 89% evidence 57.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.3/35 · Revenue 23% · Profit 9.4% · Operating margin change 2 points · 88% evidence Capital efficiency 11.7/25 · ROCE 17.3% · Operating margin 35% · 100% evidence Valuation 8.9/20 · P/E 46× · PEG 1.66 · 65% evidence Relative strength 17.2/20 · Lead over its industry 6.7% · Lead over NIFTY 500 15.6% · 1 year -0.5% · 100% evidence · 10 of 12 weeks ahead Exact sum: 19.3 + 11.7 + 8.9 + 17.2 = 57.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Dr Lal Pathlabs Ltd](https://www.sectoralpha.in/stocks/dr-lal-pathlabs-ltd) LALPATHLAB · leader · Evidence leans up · 96% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.4/35 · Revenue 14.3% · Profit 5% · Operating margin change 2 points · 88% evidence Capital efficiency 18.5/25 · ROCE 28% · Operating margin 31% · 100% evidence Valuation 9.3/20 · P/E 56.9× · PEG 1.29 · 100% evidence Relative strength 16.5/20 · Lead over its industry 15.5% · Lead over NIFTY 500 24.4% · 1 year 21.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 12.4 + 18.5 + 9.3 + 16.5 = 56.7 · What this means: Relative strength against the index is 24.4%, and revenue and profit growth are weak. 7. [3B Blackbio DX Ltd](https://www.sectoralpha.in/stocks/3b-blackbio-dx-ltd) 3BBLACKBIO · breaking out · Evidence leans up · 78% evidence 50.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.8/35 · Revenue 54.3% · Profit 14.7% · Operating margin change -27.8 points · 83% evidence Capital efficiency 16.6/25 · ROCE 25.5% · Operating margin 25.4% · 76% evidence Valuation 9.5/20 · P/E 20× · PEG n/a · 50% evidence Relative strength 9.0/20 · Lead over its industry -7% · Lead over NIFTY 500 1.2% · 1 year -5.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.8 + 16.6 + 9.5 + 9 = 50.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Krsnaa Diagnostics Ltd](https://www.sectoralpha.in/stocks/krsnaa-diagnostics-ltd) KRSNAA · breaking out · Evidence leans down · 81% evidence 49.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.7/35 · Revenue 10.3% · Profit 21% · Operating margin change -2 points · 88% evidence Capital efficiency 9.1/25 · ROCE 12.7% · Operating margin 25% · 100% evidence Valuation 18.9/20 · P/E 16.8× · PEG 0.57 · 100% evidence Relative strength 7.9/20 · Lead over its industry n/a · Lead over NIFTY 500 -13.7% · 1 year -35.1% · 25% evidence · 1 of 12 weeks ahead Exact sum: 13.7 + 9.1 + 18.9 + 7.9 = 49.6 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 9. [Vimta Labs Ltd](https://www.sectoralpha.in/stocks/vimta-labs-ltd) VIMTALABS · quiet · Most evidence points down · 100% evidence 30.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.3/35 · Revenue 11.7% · Profit 2.5% · Operating margin change 0 points · 100% evidence Capital efficiency 15.7/25 · ROCE 25.2% · Operating margin 34% · 100% evidence Valuation 4.6/20 · P/E 26.6× · PEG 2.75 · 100% evidence Relative strength 1.5/20 · Lead over its industry -12.6% · Lead over NIFTY 500 -5.4% · 1 year -33.2% · 100% evidence · 8 of 12 weeks ahead Exact sum: 8.3 + 15.7 + 4.6 + 1.5 = 30.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Diagnostics](https://www.sectoralpha.in/sectors/diagnostics), all 9 compared on one page. ## Which companies are close to Suraksha Diagnostic in size? Suraksha Diagnostic is the 6th largest of 9 Diagnostics companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Metropolis Healthcare, Thyrocare Technologies and Vimta Labs. Just below it: Krsnaa Diagnostics, 3B Blackbio DX and One Global Service Provider. ### Diagnostics companies close in size

1. [Metropolis Healthcare Ltd](https://www.sectoralpha.in/stocks/metropolis-healthcare-ltd) ₹11,320 crore
2. [Thyrocare Technologies Ltd](https://www.sectoralpha.in/stocks/thyrocare-technologies-ltd) ₹7,263 crore
3. [Vimta Labs Ltd](https://www.sectoralpha.in/stocks/vimta-labs-ltd) ₹2,168 crore
4. Suraksha Diagnostic Ltd ₹1,648 crore
5. [Krsnaa Diagnostics Ltd](https://www.sectoralpha.in/stocks/krsnaa-diagnostics-ltd) ₹1,634 crore
6. [3B Blackbio DX Ltd](https://www.sectoralpha.in/stocks/3b-blackbio-dx-ltd) ₹1,112 crore
7. [One Global Service Provider Ltd](https://www.sectoralpha.in/stocks/one-global-service-provider-ltd) ₹858 crore

[All 9 Diagnostics companies, largest first](https://www.sectoralpha.in/sectors/diagnostics#all-companies)

### Companies close in size in other industries

1. [Team Lease Services Ltd](https://www.sectoralpha.in/stocks/team-lease-services-ltd) ₹1,651 crore · Services - Others
2. [Brightcom Group Ltd](https://www.sectoralpha.in/stocks/brightcom-group-ltd) ₹1,649 crore · IT Enabled Services/Business Process Outsourcing
3. Suraksha Diagnostic Ltd ₹1,648 crore
4. [I G Petrochemicals Ltd](https://www.sectoralpha.in/stocks/i-g-petrochemicals-ltd) ₹1,636 crore · Chemicals - Organic - Maleic Anhydride
5. [Krsnaa Diagnostics Ltd](https://www.sectoralpha.in/stocks/krsnaa-diagnostics-ltd) ₹1,634 crore · Diagnostics

## What else do people ask about Suraksha Diagnostic? ### What is Suraksha Diagnostic's share price today? Suraksha Diagnostic Ltd's share price is ₹323.70, +1.8% over the past year. The whole company is worth ₹1,688 Cr on the market. In the last 52 weeks it traded between ₹236 to ₹350; today it is 77% of the way up from the low, 8.5% above its 200-day average (as of 3 November 2026). ### What were Suraksha Diagnostic's latest quarterly results? Suraksha Diagnostic Ltd reported revenue of ₹88.0 Cr and net profit of ₹13.0 Cr for the Jun 2026 quarter. Revenue rose 20.5% and profit rose 44.4% compared with a year earlier. Earnings per share were ₹2.50. The operating margin was 35.0%, 2.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Suraksha Diagnostic's market cap? Suraksha Diagnostic Ltd's market capitalisation is ₹1,688 Cr at a share price of ₹323.70. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Suraksha Diagnostic performing? Suraksha Diagnostic Ltd's share price has been rising for 8 weeks. In its latest quarter, revenue rose 20.5% and profit rose 44.4% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 14 weeks running (as of 3 November 2026). ### Will Suraksha Diagnostic's share price go up? This page does not forecast Suraksha Diagnostic Ltd's share price. What it shows instead: the share price is ₹323.70, and it has been rising for 8 weeks. Its P/E of 47.1× is higher than 56% of its own last 2 years (as of 3 November 2026). ### Who owns Suraksha Diagnostic? Promoters own 49.1% of Suraksha Diagnostic Ltd, foreign institutions 14.0%, domestic institutions 21.6% and the public 15.4% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 1.4 percentage points over 7 quarters (as of 3 November 2026). ### Does Suraksha Diagnostic have too much debt? Suraksha Diagnostic Ltd has a moderate amount of debt: its debt is 0.53× its equity, and its operating profit is 7 times its interest bill. FY26 borrowings were ₹130 Cr against equity of ₹244 Cr. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Suraksha Diagnostic in its business cycle? Suraksha Diagnostic Ltd's FY26 operating margin was 31.0%, against a 7-year range of 18.0% to 33.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 35.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Suraksha Diagnostic story? Biggest thing to watch: the price has already been rising for 8 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Suraksha Diagnostic a stock worth studying right now? What the numbers show: Suraksha Diagnostic Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Suraksha Diagnostic share price forecast for 2026? What management itself guided: Genomics growth indicated around 20-odd% quarter-on-quarter for FY27; exact scope was not clarified. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india

This is research, not advice. We’re not SEBI-registered.